Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes & aspirin

This article was originally published in The Tan Sheet

Executive Summary

Nearly half of American adults with diabetes are not using aspirin therapy to reduce their risk of recurrent heart attack or stroke, nor have they discussed such therapy with their physician, according to a survey released Nov. 21 by the American College of Preventive Medicine. Results were drawn from an eight-day online survey of 1,299 consumers over the age of 40 that was conducted in October 2004. The survey was conducted by Harris Interactive and was supported by an unrestricted educational grant from Bayer Healthcare. Approximately 15% of the respondents indicated they have diabetes, which places them at higher risk of cardiovascular-related events, according to the American Diabetes Association. While nearly half of the group with diabetes considered themselves "extremely knowledgeable" about aspirin, only 25% agreed that "the benefits of aspirin therapy strongly outweigh the risks"...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel